GPC3 and hepatocellular carcinoma: The combination of EpCAM, ASGPR, and GPC3 antibodies in the so-called NanoVelcro CTC Assay resulted in HCC CTCs detection in up to 97.6% of patients with HCC at various stages, being the number of CTCs associated with clinical outcomes.